Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma

Published:2018-10-30 Issue:1 Volume:144 Page:169-177
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Zhao Bin¹^ORCID,Zhao Hong²,Zhao Jiaxin³

Affiliation:

1. The Second Affiliated Hospital & Yuying Children's Hospital; Wenzhou Medical University; Wenzhou China

2. The Third Affiliated Hospital of Harbin Medical University; Harbin China

3. The Fourth Affiliated Hospital of Harbin Medical University; Harbin China

Funder

National Natural Science Foundation of China

Natural Science Foundation of Heilongjiang Province

Health and Family Planning Commission Foundation of Heilongjiang Province

Start-up Foundation of Harbin Medical University

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ijc.31813/fullpdf

Reference32 articles.

1. A new understanding in the epidemiology of melanoma;Erdei;Expert Rev Anticancer Ther,2010

2. Malignant melanoma;Califano;Facial Plast Surg Clin N Am,2009

3. Targeted agents and immunotherapies: optimizing outcomes in melanoma;Luke;Nat Rev Clin Oncol,2017

4. Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers;Grigg;Semin Oncol,2016

5. Radiotherapy and immune checkpoints inhibitors for advanced melanoma;Filippi;Radiother Oncol,2016

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials;eClinicalMedicine;2023-09

2. Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma;Journal of Clinical Oncology;2022-04-01

3. Efficacy and safety profile of avelumab monotherapy;Critical Reviews in Oncology/Hematology;2021-10

4. Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy;Cancers;2021-08-19

5. Complete response to immunotherapy in a nonagenarian patient with metastatic melanoma;BMJ Case Reports;2020-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3